title: The effect of the structure of branched polypeptide carrier on intracellular delivery of daunomycin.
abstract: The conjugate of acid labile cis-aconityl-daunomycin (cAD) with branched chain polypeptide, poly[Lys(Glui-DL-Alam)] (EAK) was very effective against L1210 leukemia in mice. However, Dau attached to a polycationic polypeptide, poly[Lys(Seri-DL-Alam)] (SAK) exhibited no in vivo antitumor effect. In order to understand this difference we have performed comparative in vitro studies to dissect properties related to interaction with the whole body (e.g., biodistribution) from those present at cellular or even molecular level. We report here (a) the kinetics of acid-induced Dau liberation, (b) interaction with DPPC phospholipid bilayer, (c) in vitro cytotoxic effect on different tumor cells, and (d) intracellular distribution in HL-60 cells of polycationic (cAD-SAK) and amphoteic (cAD-EAK) conjugates. Fluorescence properties of the two conjugates are also reported. Our findings demonstrate that the kinetics of the drug release, intracellular distribution and in vitro cytotoxic effect are rather similar, while the effect on DPPC phospholipid bilayer and fluorescence properties of the two conjugates are not the same. We also found that the in vitro cytotoxicity is cell line dependent. These observations suggest that the structure of the polypeptide carrier could have marked influence on drug uptake related events.
authors.affiliation: Research Group of Peptide Chemistry, Hungarian Academy of Sciences, Eötvös L. University, Budapest 112, POB 32 H-1518, Hungary.
authors.forename: Judit
authors.initials: J
authors.lastname: Reményi
authors.forename: Gabriella
authors.initials: G
authors.lastname: Csík
authors.forename: Péter
authors.initials: P
authors.lastname: Kovács
authors.forename: Francesca
authors.initials: F
authors.lastname: Reig
authors.forename: Ferenc
authors.initials: F
authors.lastname: Hudecz
mesh_terms: D015060:1,2-Dipalmitoylphosphatidylcholine / Q000737:chemistry; D000818:Animals; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism; D004337:Drug Carriers / Q000737:chemistry*; D018922:HL-60 Cells; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D007939:Leukemia L1210 / Q000188:drug therapy; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy; D008081:Liposomes / Q000737:chemistry; D051379:Mice; D015394:Molecular Structure; D010455:Peptides / Q000737:chemistry*; D011506:Proteins / Q000737:chemistry; D014407:Tumor Cells, Cultured
chemical_list: D004337:Drug Carriers; D036341:Intercellular Signaling Peptides and Proteins; D008081:Liposomes; D010455:Peptides; D011506:Proteins; C512363:poly(lysyl(seryl(i)-alanyl(m))); C112497:poly(lysyl-(glutamyl(i)-alanine(m))); D015060:1,2-Dipalmitoylphosphatidylcholine; C032833:N-aconityldaunomycin; D003630:Daunorubicin